DAPAGLIFLOZIN AND METFORMIN (dapagliflozin || metformin) by Sinotherapeutics Inc is sodium-glucose cotransporter 2 (sglt2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Approved for end stage kidney disease, cardiovascular death, hospitalization for heart failure in patients with chronic kidney disease at risk of progression and 7 more indications.
Drug data last refreshed 1h ago
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, and…
Worked on DAPAGLIFLOZIN AND METFORMIN at Sinotherapeutics Inc? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State